I am working as a government contractor at ARPA-H in Health Science Futures.

DEM is developing myeloid checkpoint therapies to harness the power of the innate immune system, utilizing CRISPR screens to uncover novel modulators of innate immune cell recognition of tumor cells.

Axial Biotherapeutics is focused on the gut-brain axis. We are developing microbiome-inspired therapies to treat autism spectrum disorders and Parkinson's Disease. Our immuno-oncology program is developing therapies to enhance the efficacy of cancer immunotherapies.

Sextant Biosciences is a synthetic biology company providing the next-generation discovery platform for preclinical oncology drug R&D. Our platform is the follow-on tech to CRISPR-based drug target assessments and is the only gene expression technology that can mimic pharmacology in preclinical tumor models.Our technology is unique and controls gene expression at the level of translation, making it the fastest gene expression system in the world and enabling novel experimental designs. It can mimic pharmacology in preclinical tumor models, enabling in vivo confirmation of a target's efficacy before beginning chemistry synthesis, saving time, money and resources.Sextant Biosciences - Better direction for preclinical pharmacology.

Sextant Therapeutics has identified critical regulators of cell death to enable Tumor-targeted Immuno-oncology. This approach modulates the way cancer cells die from cytotoxic therapies to then trigger tumors to recruit cancer-killing and tumor-suppressive immune responses. This approach complements existing IO strategies that target the immune system, such as checkpoint inhibitors or vaccines.Sextant Therapeutics is looking for partners with cytotoxic clinical assets to develop first-in-class Immuno-oncology therapies that target the tumor itself to drive potent anti-cancer immune responses.

Research included developing several gene expression systems to model cancer and to understand how tumors interact with the immune system.